

Table S3. Baseline clinical characteristics of un-censored patients with or without AISC.

	Total cohort	NO-AISC	AISC	P-value
	n=34	n=10	n=24	
Age (year)	52.85±12.37	59.7±9.67	50.0±12.45	<b>0.035</b>
Male/Female (n)	19/15	5/5	14/10	0.947
BMI (kg/m <sup>2</sup> )	24.01±3.21	23.67±3.83	24.15±3.00	0.698
ECoG performance status				1.000
0 (%)	23 (67.65)	7 (70.00)	16 (66.67)	
1 (%)	7 (20.59)	2 (20.00)	5 (20.83)	
2 (%)	4 (11.76)	1 (10.00)	3 (12.50)	
Hypertension (%)	4 (11.76)	3 (30.00)	1 (4.17)	0.122
Antihypertensive treatment	4 (11.76)	3 (30.00)	1 (4.17)	0.122
ACEI/ARB	3	2	1	
Beta-blockers	1	1	0	
Diabetes mellitus (%)	3 (8.82)	2 (20.00)	1 (4.17)	0.412
Smoking (%)	11 (32.35)	5 (50.00)	6 (25.00)	0.309
Drinking (%)	7 (20.59)	2 (20.00)	5 (20.83)	1.000
Heart rate	81.03±11.08	84.60±13.53	79.54±9.83	0.231
LVEF (%)	65.0 (63.0, 67.0)	64.0 (62.0, 67.3)	66.0 (64.0, 67.0)	0.270
FS (%)	35.74±2.12	35.10±2.28	36.0±2.04	0.266
GLS (-%)	21.0 (19.0, 22.0)	18.0 (17.0, 20.0)	22.0 (21.0, 22.8)	<b>&lt;0.001</b>
LVDd (mm)	46.62±3.08	45.61±3.41	47.04±2.90	0.218
LVMi (g/m <sup>2</sup> )	94.04±16.26	93.27±18.87	94.36±15.78	0.862
E (cm/s)	70.87±12.84	66.43±11.78	72.73±13.04	0.197
e'(cm/s)	7.59±1.77	6.90±1.88	7.88±1.68	0.144
E/e'	9.66±2.17	9.95±1.79	9.54±2.34	0.626
NT-proBNP (ng/L)	46.00 (28.50, 109.00)	78.50 (31.50, 133.25)	41.00 (28.00, 122.00)	0.308
cTnT (ng/mL)	0.004 (0.000, 0.007)	0.004 (0.000, 0.008)	0.004 (0.000, 0.007)	0.816
HsCRP	2.28 (0.95, 17.18)	1.62 (0.54, 13.79)	3.84 (1.21, 20.00)	0.216
TC (mmol/L)	4.07±0.95	4.38±1.31	3.95±0.75	0.219
TG (mmol/L)	1.40 (1.12, 1.63)	1.54 (1.67, 1.85)	1.38 (1.10, 1.56)	0.344
LDL-C (mmol/L)	2.59±0.83	2.73±1.15	2.53±0.68	0.530
HDL-C (mmol/L)	1.06±0.38	1.21±0.56	1.00±0.26	0.128
HDL-C group*				<b>0.019</b>
High (%)	12 (35.29)	7 (70.00)	5 (20.83)	
Low (%)	22 (64.71)	3 (30.00)	19 (79.17)	

\*High HDL-C: HDL-C $\geq$ 1.16mmol/L. Low HDL-C: HDL-C $<$ 1.16mmol/L.

AISC: anthracycline-induced subclinical cardiotoxicity; AST: aspartate transaminase; ALT: alanine aminotransferase; BMI: body mass index; cTnT: cardiac troponin T; ECoG: Eastern Cooperative Oncology Group; FS: fractional shortening; GLS: global longitudinal peak systolic strain; HDL-C: high-density lipoprotein cholesterol; HsCRP: high sensitivity C-reactive protein; LVEF: left ventricular ejection fraction; LVDd: left ventricular diastolic dimension; LVMi: left ventricular mass index; LDL-C: low-density lipoprotein cholesterol; NT-proBNP: N terminal-pro brain natriuretic peptide; TC: total

cholesterol; TG: total triglyceride.